Personalized medicine of esophageal cancer

J Cancer Res Ther. 2012 Jul-Sep;8(3):343-7. doi: 10.4103/0973-1482.103510.

Abstract

The fatality rate of esophageal carcinomas is high in developing countries, making effective treatment desirable. Traditional treatment has now entered into the platform, and treatments based on the detection of biomarkers increasingly become a trend. This review presents several biomarkers of esophageal cancer, including chemotherapy-related biomarkers and targeted drug-related biomarkers, and the correlation of these biomarkers with drug response.

Publication types

  • Review

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
  • BRCA1 Protein / metabolism
  • Biomarkers, Tumor / genetics*
  • DNA-Binding Proteins / metabolism
  • Developing Countries
  • Endonucleases / metabolism
  • ErbB Receptors / metabolism
  • Esophageal Neoplasms / drug therapy*
  • Esophageal Neoplasms / genetics
  • Humans
  • Methylenetetrahydrofolate Reductase (NADPH2) / metabolism
  • Precision Medicine / methods*
  • Thymidylate Synthase / metabolism
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / metabolism
  • bcl-2-Associated X Protein / metabolism

Substances

  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • BRCA1 Protein
  • BRCA1 protein, human
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • bcl-2-Associated X Protein
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Thymidylate Synthase
  • EGFR protein, human
  • ErbB Receptors
  • ERCC1 protein, human
  • Endonucleases